metastatic colorectal cancer
FDA Approves Lumakras With Vectibix for KRAS G12C–Mutated Colorectal Cancer
The FDA has approved Lumakras with Vectibix for adult patients with KRAS G12C–mutated metastatic colorectal ...
JANUARY 21, 2025
FDA Grants Accelerated Approval to Braftovi for Some Patients With Metastatic Colorectal Cancer
The FDA granted accelerated approval to Braftovi with cetuximab and mFOLFOX6 for patients with metastatic ...
JANUARY 2, 2025
FDA Approves Fruzaqla in Refractory Metastatic Colorectal Cancer
The FDA approved Fruzaqla for adult patients with metastatic colorectal cancer who received certain prior ...
NOVEMBER 9, 2023
New Dosing Regimen Approved for Erbitux
The FDA approved a regimen of 500 mg/m2 of cetuximab (Erbitux, ImClone) given intravenously over 120 minutes every ...
APRIL 9, 2021
FDA Grants New Indication for Opdivo + Yervoy Combo in mCRC
The FDA granted a new indication for Opdivo and Yervoy to treat adults and children 12 years of age and older with ...
JULY 12, 2018
